Metsera Reports Once-Monthly Amylin Analogue Matches GLP-1 Efficacy in Early Phase 1 Results
Metsera’s experimental drug, MET-233i, is a long-acting amylin analogue engineered to regulate blood sugar and appetite.
The Phase 1 trial involved 80 overweight or obese participants and showed 8.4% placebo-adjusted weight loss at 36 days with the highest dose (1.2 mg, five weekly doses).
MET-233i has a half-life of 19 days, supporting once-monthly dosing—potential advantage over current weekly GLP-1 drugs.
The drug demonstrated a relatively clean safety profile with mild and transient gastrointestinal side effects.
Results indicate MET-233i’s efficacy is competitive with current GLP-1 therapies, but with less frequent dosing.
Metsera plans to continue monotherapy studies and is also exploring combining MET-233i with an ultra-long-acting GLP-1 analogue.